Fatty acid amide hydrolase (FAAH) is an emerging target for the treatment of neuropathic pain. The enzyme FAAH degrades anandamide, which is an endogenous cannabinoid that produces an analgesic effect in response to pain and nerve injury. FAAH inhibition increases the duration of anandamide's analgesic effect, prolonging pain relief at the site of release.

Infinity is in Phase 1 clinical development with IPI-940, its selective, orally administered inhibitor of FAAH, and anticipates completing Phase 1 development in 2010. Infinity’s FAAH program is part of its global strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited.